DiaMedica Presents at AHA International Stroke Conference

DiaMedica Therapeutics, a biopharmaceutical firm at the forefront of clinical-stage development, is gearing up to unveil the framework and rationale for its pivotal ReMEDy2 trial. This trial is designed to test the efficacy of their drug candidate, DM199, in treating patients with acute ischemic stroke (AIS) who are not eligible for traditional treatments such as tissue plasminogen activator (tPA) or mechanical thrombectomy.

The company has slated a poster presentation detailing the ReMEDy2 trial's methodology at the esteemed American Heart Association's 2024 International Stroke Conference. This event is set to take place in Phoenix, Arizona, from February 7th to 9th, 2024. The poster, titled "Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study To Evaluate The Safety And Efficacy Of Dm199 For The Treatment Of Acute Ischemic Stroke (ReMEDy2 Trial)," will be on display in Poster Hall 5-6 at a specific board, with a dedicated time slot for questions and discussions led by Dr. Scott Kasner, the trial's principal investigator.

DiaMedica's commitment to advancing stroke treatment is evident through their lead candidate, DM199, which represents a novel approach in pharmaceutical intervention. This recombinant form of the KLK1 protein has shown promise in Asia for treating AIS and other vascular conditions, marking a significant step towards improving patient outcomes.

The company's presence at the conference will also include an exhibition booth, providing an opportunity for attendees to engage with DiaMedica's representatives and learn more about their research and development efforts. As a clinical-stage entity, DiaMedica is dedicated to translating scientific innovation into tangible therapeutic solutions for serious medical conditions, with a particular focus on AIS.

DiaMedica Therapeutics is a company with a clear mission: to enhance the quality of life for individuals affected by severe diseases, particularly acute ischemic stroke. Their dedication to clinical research and development is a testament to their pursuit of innovative treatments that could potentially transform the landscape of stroke care.